At present, the world's only all human CD20 monoclonal antibody customized for patients with multiple sclerosis (quanxinda) issued its first prescription in China on March 24, marking the official landing of breakthrough innovative drugs in the field of global multiple sclerosis treatment in China. Alpha tomumab was approved by the State Drug Administration in December 2021 for the treatment of recurrent multiple sclerosis in adults, including clinically isolated syndrome, relapsing remitting multiple sclerosis and active secondary progressive multiple sclerosis. Professor Dong Qiang, director of Neurology Department of Huashan Hospital Affiliated to Fudan University, said: "As a first-line treatment in remission, disease modifying drugs can help patients effectively reduce disease recurrence and control disease progression by regulating immune inflammatory response. Alfa tomumab not only achieves a balance in effectiveness and safety, but also has a relatively convenient way of administration. Today, I am glad to see that many patients in China use Alfa tomumab for the first time, and I hope more patients can return to health and freedom through active treatment Life. " Multiple sclerosis is an immune-mediated disease characterized by inflammatory demyelinating lesions of the central nervous system. A number of research data show that B cells and their autoantibodies play a more important role in the pathogenesis of MS. Alpha tomumab plays a role by combining with two unique epitopes on B cells expressing CD20 to induce the dissolution and elimination of pathogenic B cells. While realizing precise treatment, it retains the reconstruction function of B cells and the immune monitoring function of plasma cells. It is reported that in order to benefit Chinese patients for the first time, Alfa tomumab has passed the drug inspection after being approved to be listed in China. The first batch of drugs have been sent to 32 cities in China, such as Beijing, Shanghai and Guangzhou. (outlook new era)
Edit：Yuanqi Tang Responsible editor：Xiao Yu
Source：
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Recommended Reading Change it 
Home
